FLT3 mutations in myeloid sarcoma

M. Ali Ansari-Lari, Ching Fen Yang, Rima Tinawi-Aljundi, Lisa A Cooper, Patricia Long, Robert H. Allan, Michael J Borowitz, Karin D. Berg, Kathleen M. Murphy

Research output: Contribution to journalArticle

Abstract

Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms-like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20-40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas-containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.

Original languageEnglish (US)
Pages (from-to)785-791
Number of pages7
JournalBritish Journal of Haematology
Volume126
Issue number6
DOIs
StatePublished - Sep 2004

Fingerprint

fms-Like Tyrosine Kinase 3
Myeloid Sarcoma
Mutation
Acute Myeloid Leukemia
Leukemia
Myeloproliferative Disorders
Point Mutation
Aspartic Acid
Base Pairing
Neoplasms

Keywords

  • Acute myeloid leukaemia
  • FLT3
  • Molecular pathology
  • Mutation
  • Myeloid sarcoma

ASJC Scopus subject areas

  • Hematology

Cite this

Ansari-Lari, M. A., Yang, C. F., Tinawi-Aljundi, R., Cooper, L. A., Long, P., Allan, R. H., ... Murphy, K. M. (2004). FLT3 mutations in myeloid sarcoma. British Journal of Haematology, 126(6), 785-791. https://doi.org/10.1111/j.1365-2141.2004.05124.x

FLT3 mutations in myeloid sarcoma. / Ansari-Lari, M. Ali; Yang, Ching Fen; Tinawi-Aljundi, Rima; Cooper, Lisa A; Long, Patricia; Allan, Robert H.; Borowitz, Michael J; Berg, Karin D.; Murphy, Kathleen M.

In: British Journal of Haematology, Vol. 126, No. 6, 09.2004, p. 785-791.

Research output: Contribution to journalArticle

Ansari-Lari, MA, Yang, CF, Tinawi-Aljundi, R, Cooper, LA, Long, P, Allan, RH, Borowitz, MJ, Berg, KD & Murphy, KM 2004, 'FLT3 mutations in myeloid sarcoma', British Journal of Haematology, vol. 126, no. 6, pp. 785-791. https://doi.org/10.1111/j.1365-2141.2004.05124.x
Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper LA, Long P, Allan RH et al. FLT3 mutations in myeloid sarcoma. British Journal of Haematology. 2004 Sep;126(6):785-791. https://doi.org/10.1111/j.1365-2141.2004.05124.x
Ansari-Lari, M. Ali ; Yang, Ching Fen ; Tinawi-Aljundi, Rima ; Cooper, Lisa A ; Long, Patricia ; Allan, Robert H. ; Borowitz, Michael J ; Berg, Karin D. ; Murphy, Kathleen M. / FLT3 mutations in myeloid sarcoma. In: British Journal of Haematology. 2004 ; Vol. 126, No. 6. pp. 785-791.
@article{8b737c4daa5847cd91dcbacd6f2f346a,
title = "FLT3 mutations in myeloid sarcoma",
abstract = "Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms-like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15{\%}); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20-40{\%} of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas-containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.",
keywords = "Acute myeloid leukaemia, FLT3, Molecular pathology, Mutation, Myeloid sarcoma",
author = "Ansari-Lari, {M. Ali} and Yang, {Ching Fen} and Rima Tinawi-Aljundi and Cooper, {Lisa A} and Patricia Long and Allan, {Robert H.} and Borowitz, {Michael J} and Berg, {Karin D.} and Murphy, {Kathleen M.}",
year = "2004",
month = "9",
doi = "10.1111/j.1365-2141.2004.05124.x",
language = "English (US)",
volume = "126",
pages = "785--791",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - FLT3 mutations in myeloid sarcoma

AU - Ansari-Lari, M. Ali

AU - Yang, Ching Fen

AU - Tinawi-Aljundi, Rima

AU - Cooper, Lisa A

AU - Long, Patricia

AU - Allan, Robert H.

AU - Borowitz, Michael J

AU - Berg, Karin D.

AU - Murphy, Kathleen M.

PY - 2004/9

Y1 - 2004/9

N2 - Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms-like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20-40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas-containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.

AB - Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms-like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20-40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas-containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.

KW - Acute myeloid leukaemia

KW - FLT3

KW - Molecular pathology

KW - Mutation

KW - Myeloid sarcoma

UR - http://www.scopus.com/inward/record.url?scp=4644219519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644219519&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.05124.x

DO - 10.1111/j.1365-2141.2004.05124.x

M3 - Article

C2 - 15352981

AN - SCOPUS:4644219519

VL - 126

SP - 785

EP - 791

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -